8-K: Supernus Pharmaceuticals Announces Executive Compensation Adjustments

Supernus Pharmaceuticals has increased the base salaries and awarded bonuses and stock options to its executive officers, effective January 1, 2024.

Summary

• Supernus Pharmaceuticals has modified the compensation for its executive officers.
• The annual base salaries for several executives were increased, effective January 1, 2024.
• CEO Jack A. Khattar's base salary increased to $1,001,500, and he received a $830,588 bonus, along with stock options and performance share units (PSUs).
• CFO Timothy C. Dec's base salary increased to $485,500, and he received a $210,558 bonus, along with stock options, restricted stock units (RSUs), and PSUs.
• Other executives, including Padmanabh P. Bhatt, Jonathan Rubin, Tami T. Martin, and Frank Mottola, also received salary increases, bonuses, and stock-based awards.
• The stock options and RSUs vest annually over four years.
• The exercise price for the stock options is $27.94 per share, based on the closing price on February 22, 2024.
• PSUs vest based on the achievement of performance goals set by the Compensation Committee.

Sentiment

Score: 7

Explanation: The document reflects standard corporate practice of adjusting executive compensation. The sentiment is neutral to positive as it indicates the company is taking steps to retain and motivate its leadership team.

Positives

• Executive compensation adjustments are consistent with the company's industry peer group.
• The compensation adjustments were recommended by an independent compensation consulting company, Aon plc.
• The use of stock options and performance-based units aligns executive interests with company performance.

Risks

• The vesting of PSUs is dependent on the achievement of performance goals, which introduces uncertainty.
• The Compensation Committee has sole discretion in determining if performance goals have been achieved.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting of stock options and performance share units.

Management Comments

• The increases in annual base salary became effective as of January 1, 2024, and are consistent with the Company's industry peer group.
• The increases were recommended to the Committee by the Human Capital Solutions practice of Aon plc, its independent compensation consulting company.

Industry Context

Executive compensation adjustments are a common practice in the pharmaceutical industry to attract and retain talent, and the use of stock options and performance-based units is a standard method to align executive interests with company performance.

Comparison to Industry Standards

• The document states that the compensation adjustments are consistent with the company's industry peer group, suggesting that the changes are in line with market practices.
• The use of Aon plc, a well-known compensation consulting firm, indicates that the company is using industry-standard practices for determining executive pay.
• While specific peer companies are not named, the implication is that Supernus's compensation is benchmarked against similar pharmaceutical companies.

Stakeholder Impact

• Shareholders may view the compensation adjustments as a positive sign of the company's commitment to retaining key talent.
• Employees may see the adjustments as a positive indication of the company's financial health and commitment to its leadership team.

Next Steps

• The stock options and RSUs will vest annually over a four-year period.
• The Compensation Committee will determine if performance goals for PSUs have been achieved.

Key Dates

Keywords

executive compensation, base salary, stock options, performance share units, restricted stock units, bonus, compensation committee, equity incentive plan